Antidiabetic Drugs and Their Nanoconjugates Repurposed as Novel Antimicrobial Agents against Acanthamoeba castellanii
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Acanthamoeba castellanii belonging to the T4 genotype may cause a fatal brain infection known as granulomatous amoebic encephalitis, and the vision-threatening eye infection Acanthamoeba keratitis. The aim of this study was to evaluate the antiamoebic effects of three clinically available antidiabetic drugs, Glimepiride, Vildagliptin and Repaglinide, against A. castellanii belonging to the T4 genotype. Furthermore, we attempted to conjugate these drugs with silver nanoparticles (AgNPs) to enhance their antiamoebic effects. Amoebicidal, encystation, excystation, and host cell cytotoxicity assays were performed to unravel any antiacanthamoebic effects. Vildagliptin conjugated silver nanoparticles (Vgt-AgNPs) characterized by spectroscopic techniques and atomic force microscopy were synthesized. All three drugs showed antiamoebic effects against A. castellanii and significantly blocked the encystation. These drugs also showed significant cysticidal effects and reduced host cell cytotoxicity caused by A. castellanii. Moreover, Vildagliptin-coated silver nanoparticles were successfully synthesized and are shown to enhance its antiacanthamoebic potency at significantly reduced concentration. The repurposed application of the tested antidiabetic drugs and their nanoparticles against free-living amoeba such as Acanthamoeba castellanii described here is a novel outcome that holds tremendous potential for future applications against devastating infection.
Abstract
Acanthamoeba castellanii belonging to the T4 genotype may cause a fatal brain infection known as granulomatous amoebic encephalitis, and the vision-threatening eye infection Acanthamoeba keratitis. The aim of this study was to evaluate the antiamoebic effects of three clinically available antidiabetic drugs, Glimepiride, Vildagliptin and Repaglinide, against A. castellanii belonging to the T4 genotype. Furthermore, we attempted to conjugate these drugs with silver nanoparticles (AgNPs) to enhance their antiamoebic effects. Amoebicidal, encystation, excystation, and host cell cytotoxicity assays were performed to unravel any antiacanthamoebic effects. Vildagliptin conjugated silver nanoparticles (Vgt-AgNPs) characterized by spectroscopic techniques and atomic force microscopy were synthesized. All three drugs showed antiamoebic effects against A. castellanii and significantly blocked the encystation. These drugs also showed significant cysticidal effects and reduced host cell cytotoxicity caused by A. castellanii. Moreover, Vildagliptin-coated silver nanoparticles were successfully synthesized and are shown to enhance its antiacanthamoebic potency at significantly reduced concentration. The repurposed application of the tested antidiabetic drugs and their nanoparticles against free-living amoeba such as Acanthamoeba castellanii described here is a novel outcome that holds tremendous potential for future applications against devastating infection.
참고문헌 (38)
- Seal D V, "Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment", Eye, 17, pp.893~905 (2003)
- Marciano-Cabral F, "Acanthamoeba spp, as agents of disease in humans", Clin. Microbiol. Rev, 16, pp.273~307 (2003)
- Illingworth CD, "Acanthamoeba keratitis : risk factors and outcome", Br. J. Ophthalmol, 79, pp.1078~1082 (1995)
- Visvesvara GS, "Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea", FEMS Immun. Med. Microbiol, 50, pp.1~26 (2007)
- Khan N A, "Acanthamoeba : biology and increasing importance in human health", FEMS Microbiol. Rev, 30, pp.564~595 (2006)
- Lorenzo-Morales J, "An update on Acanthamoeba keratitis : diagnosis, pathogenesis and treatment", Parasite 2015, 22, pp.10~ (2015)
- Coulon C, "Resistance of Acanthamoeba cysts to disinfection treatments used in health care settings", J. Clin. Microbiol, 48, pp.2689~2697 (2010)
- Ortillés Á, "In-vitro development of an effective treatment for Acanthamoeba keratitis", Int. J. Antimicrob. Agents, 50, pp.325~333 (2017)
- Huh AJ, ""Nanoantibiotics" : a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era", J. Control. Release, 156, pp.128~145 (2011)
- Borase HP, "Amoebicidal activity of phytosynthesized silver nanoparticles and their in vitro cytotoxicity to human cells", FEMS Microbiol. Lett, 345, pp.127~131 (2013)
- Imran M, "Synthesis, characterization and amoebicidal potential of locally synthesized TiO2 nanoparticles against pathogenic Acanthamoeba trophozoites in vitro", J. Photochem. Photobiol. B : Biol, 159, pp.125~132 (2016)
- Willcox MD, "Ability of silver-impregnated contact lenses to control microbial growth and colonisation", J. Optometry, 3, pp.143~148 (2010)
- Aqeel Y, "Gold nanoparticle conjugation enhances the antiacanthamoebic effects of chlorhexidine", Antimicrob. Agents Chemother, 60, pp.1283~1288 (2016)
- Ayaz Anwar, "Gold Nanoparticles Conjugation Enhances Antiacanthamoebic Properties of Nystatin, Fluconazole and Amphotericin B", Journal of Microbiology and Biotechnology, 29(1), pp.171~177 (2019), 한국미생물·생명공학회[DOI]
- Anwar A, "Combating Acanthamoeba spp, cysts: what are the options?", Parasit. Vectors, 11, pp.26~ (2018)
- Dudley R, "Carbohydrate analysis of Acanthamoeba castellanii", Exp. Parasitol, 122, pp.338~343 (2009)
- Lorenzo-Morales J, "Glycogen phosphorylase in Acanthamoeba spp,: determining the role of the enzyme during the encystment process using RNA interference", Eukaryot. Cell, 7, pp.509~517 (2008)
- Abjani F, "Targeting cyst wall is an effective strategy in improving the efficacy of marketed contact lens disinfecting solutions against Acanthamoeba castellanii cysts", Cont. Lens Anterior Eye, 39, pp.239~243 (2016)
- Sissons J, "Use of in vitro assays to determine effects of human serum on biological characteristics of Acanthamoeba castellanii", J. Clin. Microbiol, 44, pp.2595~2600 (2006)
- Anwar A, "Silver nanoparticle conjugation affects antiacanthamoebic activities of amphotericin B, nystatin, and fluconazole", Parasitol. Res, 117, pp.265~271 (2018)
- Lakhundi S, "Inefficacy of marketed contact lens disinfection solutions against keratitis-causing Acanthamoeba castellanii belonging to the T4 genotype", Exp. Parasitol, 141, pp.122~128 (2014)
- Sissons J, "Acanthamoeba castellanii induces host cell death via a phosphatidylinositol 3-kinase-dependent mechanism", Infect. Immun, 73, pp.2704~2708 (2005)
- Anwar A, "Gold nanoparticle-conjugated cinnamic acid exhibits antiacanthamoebic and antibacterial properties", Antimicrob. Agents Chemother, 62, pp.e00630~e00618 (2018)
- Masri A, "Silver nanoparticle conjugation enhanced antibacterial efficacy of clinically approved drugs Cephradine and Vildagliptin", Antibiotics, 7, pp.100~ (2018)
- Debnath A, "In vitro efficacy of corifungin against Acanthamoeba castellanii trophozoites and cysts", Antimicrob. Agents Chemother, 58, pp.1523~1528 (2014)
- Campbell RK, "Glimepiride : role of a new sulfonylurea in the treatment of type 2 diabetes mellitus", Ann. Pharmacother, 32, pp.1044~1052 (1998)
- Muller G, "The mode of action of the antidiabetic drug glimepiride-beyond insulin secretion", Immunol. Endocr. Metab. Agents Med. Chem, 5, pp.499~518 (2005)
- Abd El-Wahed M, "Synthesis of several new lanthanide Glimepiride complexes for evaluation of microbial activity", Russ. J. Gen. Chem, 83, pp.2438~2446 (2013)
- Ahrén B, "Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans", Diabetes Obes. Metab, 13, pp.775~783 (2011)
- Al-Abdullah E, "Synthesis, antimicrobial and hypoglycemic activities of novel N-(1-adamantyl)carbothioamide derivatives", Molecules, 20, pp.8125~8143 (2015)
- Waghulde M, "Comparative study of encapsulated vildagliptin microparticles produced by spray drying and solvent evaporation technique", Drying Technol, 35, pp.1644~1654 (2017)
- Baig MMFA, "Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus", Biomed. Pharmacother, 97, pp.1250~1258 (2018)
- Malaisse WJ, "Repaglinide, a new oral antidiabetic agent : a review of recent preclinical studies", Eur. J. Clin. Invest, 29, pp.21~29 (1999)
- Baig AM, "In vitro efficacies of clinically available drugs against growth and viability of an Acanthamoeba castellanii keratitis isolate belonging to the T4genotype", Antimicrob. Agents Chemother, 57, pp.3561~3567 (2013)
- Baig AM, "Recommendations for the management of Acanthamoeba keratitis", J. Med. Microbiol, 63, pp.770~771 (2014)
- Kumari A, "Biodegradable polymeric nanoparticles based drug delivery systems", Colloids Surf. B: Biointerfaces, 75, pp.1~8 (2010)
- De las Heras Alarcón C, "Stimuli responsive polymers for biomedical applications", Chem. Soc. Rev, 34, pp.276~285 (2005)
- Sondi I, "Silver nanoparticles as antimicrobial agent : a case study on E. coli as a model for Gram-negative bacteria", J. Colloids Interface Sci, 275, pp.177~182 (2004)